News

The investment allows HBYS commercial team to also sell third party products in all provinces in China. HBYS will invest $3.2m for a 60% equity interest in NBHG

The lymph nodes are located using a radioactive signal with a hand-held radioactive tracer and are surgically removed and analyzed to determine if tumor cells are present. Clinical

Further, A*Star has chosen Agilent to offer automation technologies to biomedical researchers, enabling efficient drug screening in one location. A*STAR has now deployed Agilent’s dual BioCel 1200 integrated

The MAA submission was based on the RHODOS study results which was, a placebo-controlled, randomized trial and has demonstrated efficacy of idebenone in LHON. The MAA also includes

APC-100 is an orally available anti-androgenic/anti-inflammatory, signal transduction inhibitor drug. The recently issued patent strengthens company’s patent portfolio for the use of APC-100 in the treatment of early

Revolade, an oral platelet generator is used to treat thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had

The results of the trial suggested that the drug showed improvement in overall survival as comparison to placebo and has also demonstrated reduction in risk of mortality. The

The antisense drug ISIS-PTP1BRx is intended to increase the body’s sensitivity to the natural hormone insulin, helping in better glucose control for patients suffering from type 2 diabetes.

The trial was designed to investigate the tolerability, safety, efficacy and pharmacokinetics of INO-8875 delivered as an eye-drop formulation in patients with primary open-angle glaucoma or ocular hypertension.